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Prevention and Management of Metabolic diseases

EACS Guidelines
Abbreviations used throughout this document
In HIV infection, both uncontrolled replication of HIV, co-infections (e.g. HCV) and ART contribute to metabolic diseases. The prevention and management of metabolic diseases in HIV should take all these factors into consideration.
Health care professionals involved with the care of HIVinfected persons who are not familiar with the use of ART should consult HIV specialists before introducing or modifying any type of treatment that HIV patients receive.
Conversely, many HIV physicians are not specialists in metabolic diseases, and should seek proper consultation prior to engaging in the prevention and management of such conditions. Situations where consultation is generally recommended are indicated where appropriate in these guidelines.
Preventing or managing metabolic diseases in HIV often involves polypharmacy, which increases the risk of suboptimal adherence and hence may compromise the continued benefit of ART. Additionally, the possibility of drug-drug interactions with ART should be carefully considered prior to introducing any treatment. Several web-sites exist for this purpose: www.HIV-druginteractions.org, www.HIVpharmacology.com, www.AIDSinfo.nih.gov.
There is limited amount of evidence from randomised controlled trials on how to most effectively manage metabolic diseases in HIV. As a result management currently is mainly extrapolated from general medical guidelines. Based on future clinical research findings, these guidelines will be regularly updated, at www.eacs.eu. The guidelines posted on the web, as well as updated versions will contain much more detailed information and links to any other relevant websites.
HIV specific issues to be considered
■
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The current guidelines highlight metabolic diseases, which are seen frequently in the routine care of HIVinfected persons and those for which specific issues should be considered. 
t dyslipidaemia
i Treatment goal is to reduce LDL-c < cut-off levels (see 22). Check lipids (fasting) prior to initiation of therapy, 4-12 weeks after initiation or modification of therapy, and annually once levels are below cut off levels. Consult with lipid expert if treatment goal cannot be reached. ii Check AST (< x 3 ULN) and CK (< x5 ULN) prior to initiation, 4-12 weeks after treatment initiation, and then annually if within normal range. iii It is not clear whether these levels of elevated TG carry an excess CVD risk; priority should be given to reducing LDL-c to below cut-off levels (see 22). iv Combination therapy of statin and gemfibrozil (and less so other fibrates) increases risk of rhabdomyolysis and should be avoided whenever possible. ✔ Only ART modification proven to partially restore subcutaneous fat; increase in total limb fat ~400-500g/year (2005) ii An abnormal finding should be repeated before confirming the diagnosis.
Treatment recommendations
iii Is recommended in patients with fasting blood glucose 6.1 -6.9 mmol/L (110 -125 mg/dL) as it may diagnose patients with overt diabetes. Both IGT and IFG increase CV morbidity and mortality, and increase the risk of developing diabetes by 4-6 fold. These patients should be targeted for life style intervention, and their CV risk factors must be evaluated and treated. Large doses may be required (1-2 IU/kg).
Treatment of type 2 diabetes
Individualise treatment: metformin for an overweight patient, pioglitazone (rosiglitazone) for a lipoatrophic patient. Metformin and glitazones can be combined. Diabetes is typically a progressive disease and medication must be modified accordingly. There are currently no data on the use of other antidiabetic drugs (sulfonylureas, glinides, exenatide, alphaglucosidase inhibitors) in the treatment of HIV-infected patients taking ART. If treatment target cannot be reached with oral agents, insulin should be started. Start with 10 IU of long-acting insulin at bedtime. Teach the patient to self-monitor fasting glucose values and increase the dose by 2 units every 3 days until fasting plasma glucose < 6.1 mmol/l. Oral metformin should be continued with insulin therapy.
Treatment goals: glucose control (HbA1c < 6.5-7.0% without hypoglycemias, fasting plasma glucose 4-6 mmol/l (73-110 mg/dl)); normal blood lipids and blood pressure (see 22 and 36).
Acetylsalisylic acid (75-150mg/d) should be considered in all patients with diabetes.
Nephropathy and retinopathy screening should be performed as in diabetic patients without HIV.
Consultation with a specialist in diabetology is recommended. Management based on blood pressure measurement / diagnosis of hypertension -2/2-
